Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose rituximab retreatment in rheumatoid arthritis responders
2011-006001-10Phase 3Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Change in DAS28 from baseline to T14. Started Mar 2012; status: terminated.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-006001-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006001-10.